Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management
Summary: Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically useful information about prognosis and therapeutic efficacy in multiple sclerosis (MS). There is now substantial evidence for this biomarker to be used alongside magnetic resonance imaging (MRI) an...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396424000057 |
| _version_ | 1827349829132484608 |
|---|---|
| author | Mark S. Freedman Sharmilee Gnanapavan Ronald A. Booth Peter A. Calabresi Michael Khalil Jens Kuhle Jan Lycke Tomas Olsson |
| author_facet | Mark S. Freedman Sharmilee Gnanapavan Ronald A. Booth Peter A. Calabresi Michael Khalil Jens Kuhle Jan Lycke Tomas Olsson |
| author_sort | Mark S. Freedman |
| collection | DOAJ |
| description | Summary: Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically useful information about prognosis and therapeutic efficacy in multiple sclerosis (MS). There is now substantial evidence for this biomarker to be used alongside magnetic resonance imaging (MRI) and clinical measures of disease progression as a decision-making tool for the management of patients with MS. Serum NfL (sNfL) has certain advantages over traditional measures of MS disease progression such as MRI because it is relatively noninvasive, inexpensive, and can be repeated frequently to monitor activity and treatment efficacy. sNfL levels can be monitored regularly in patients with MS to determine change from baseline and predict subclinical disease activity, relapse risk, and the development of gadolinium-enhancing (Gd+) lesions. sNfL does not replace MRI, which provides information related to spatial localisation and lesion stage. Laboratory platforms are starting to be made available for clinical application of sNfL in several countries. Further work is needed to resolve issues around comparisons across testing platforms (absolute values) and normalisation (reference ranges) in order to guide interpretation of the results. |
| first_indexed | 2024-03-08T00:48:52Z |
| format | Article |
| id | doaj.art-4e3c083cc88e45e594ebc2a3e2e3dc56 |
| institution | Directory Open Access Journal |
| issn | 2352-3964 |
| language | English |
| last_indexed | 2024-03-08T00:48:52Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj.art-4e3c083cc88e45e594ebc2a3e2e3dc562024-02-15T05:24:27ZengElsevierEBioMedicine2352-39642024-03-01101104970Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis managementMark S. Freedman0Sharmilee Gnanapavan1Ronald A. Booth2Peter A. Calabresi3Michael Khalil4Jens Kuhle5Jan Lycke6Tomas Olsson7Department of Medicine (Neurology), University of Ottawa, and the Ottawa Hospital Research Institute, Ontario, Canada; Corresponding author. Department of Medicine, University of Ottawa, and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.Department of Neurology, Barts Health NHS Trust, London, England, UKDepartment of Pathology and Laboratory Medicine, University of Ottawa, The Ottawa Hospital & Eastern Ontario Regional Laboratory Association, Ontario, CanadaDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USADepartment of Neurology, Medical University of Graz, Graz, AustriaMultiple Sclerosis Centre, Neurology, Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel, SwitzerlandDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, SwedenDepartment of Clinical Neuroscience, Karolinska Institute, Solna, SwedenSummary: Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically useful information about prognosis and therapeutic efficacy in multiple sclerosis (MS). There is now substantial evidence for this biomarker to be used alongside magnetic resonance imaging (MRI) and clinical measures of disease progression as a decision-making tool for the management of patients with MS. Serum NfL (sNfL) has certain advantages over traditional measures of MS disease progression such as MRI because it is relatively noninvasive, inexpensive, and can be repeated frequently to monitor activity and treatment efficacy. sNfL levels can be monitored regularly in patients with MS to determine change from baseline and predict subclinical disease activity, relapse risk, and the development of gadolinium-enhancing (Gd+) lesions. sNfL does not replace MRI, which provides information related to spatial localisation and lesion stage. Laboratory platforms are starting to be made available for clinical application of sNfL in several countries. Further work is needed to resolve issues around comparisons across testing platforms (absolute values) and normalisation (reference ranges) in order to guide interpretation of the results.http://www.sciencedirect.com/science/article/pii/S2352396424000057Multiple sclerosisNeurofilament light chainCerebrospinal fluid biomarkersSerum biomarkers |
| spellingShingle | Mark S. Freedman Sharmilee Gnanapavan Ronald A. Booth Peter A. Calabresi Michael Khalil Jens Kuhle Jan Lycke Tomas Olsson Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management EBioMedicine Multiple sclerosis Neurofilament light chain Cerebrospinal fluid biomarkers Serum biomarkers |
| title | Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management |
| title_full | Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management |
| title_fullStr | Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management |
| title_full_unstemmed | Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management |
| title_short | Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management |
| title_sort | guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management |
| topic | Multiple sclerosis Neurofilament light chain Cerebrospinal fluid biomarkers Serum biomarkers |
| url | http://www.sciencedirect.com/science/article/pii/S2352396424000057 |
| work_keys_str_mv | AT marksfreedman guidanceforuseofneurofilamentlightchainasacerebrospinalfluidandbloodbiomarkerinmultiplesclerosismanagement AT sharmileegnanapavan guidanceforuseofneurofilamentlightchainasacerebrospinalfluidandbloodbiomarkerinmultiplesclerosismanagement AT ronaldabooth guidanceforuseofneurofilamentlightchainasacerebrospinalfluidandbloodbiomarkerinmultiplesclerosismanagement AT peteracalabresi guidanceforuseofneurofilamentlightchainasacerebrospinalfluidandbloodbiomarkerinmultiplesclerosismanagement AT michaelkhalil guidanceforuseofneurofilamentlightchainasacerebrospinalfluidandbloodbiomarkerinmultiplesclerosismanagement AT jenskuhle guidanceforuseofneurofilamentlightchainasacerebrospinalfluidandbloodbiomarkerinmultiplesclerosismanagement AT janlycke guidanceforuseofneurofilamentlightchainasacerebrospinalfluidandbloodbiomarkerinmultiplesclerosismanagement AT tomasolsson guidanceforuseofneurofilamentlightchainasacerebrospinalfluidandbloodbiomarkerinmultiplesclerosismanagement |